Mutations in sFRP1 or sFRP4 are not a common cause of craniotubular hyperostosis

Bone

Volumn 52, Issue 1, 2013, Pages

  Boudin, Eveline ^a   Piters, Elke ^a   Fijalkowski, Igor ^a   Stevenheydens, Gino ^a   Steenackers, Ellen ^a   Kuismin, Outi ^b   Moilanen, Jukka S ^b   Mortier, Geert ^a   Van Hul, Wim ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Bone; Craniotubular hyperostosis; SFRP1; SFRP4

Indexed keywords

ARGININE; RNA; SECRETED FRIZZLED RELATED PROTEIN 1; SECRETED FRIZZLED RELATED PROTEIN 2; TRYPTOPHAN;

ARTICLE; CRANIOTUBULAR HYPEROSTOSIS; EXON; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HETEROZYGOSITY; HUMAN; HYPEROSTOSIS; INTRON; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; OSSIFICATION; PREDICTION; RNA SPLICING; SEQUENCE ANALYSIS; SFRP1 GENE; SFRP2 GENE;

EID: 84868481089     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.09.034     Document Type: Article

References (34)

1. Balemans W., Ebeling M., Patel N., Van Hul E., Olson P., Dioszegi M., et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001, 10:537-543.
2. Balemans W., Patel N., Ebeling M., Van Hul E., Wuyts W., Lacza C., et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 2002, 39:91-97.
3. Brunkow M.E., Gardner J.C., Van Ness J., Paeper B.W., Kovacevich B.R., Proll S., et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001, 68:577-589.
4. Boyden L.M., Mao J., Belsky J., Mitzner L., Farhi A., Mitnick M.A., et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002, 346:1513-1521.
5. Little R.D., Carulli J.P., Del Mastro R.G., Dupuis J., Osborne M., Folz C., et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002, 70:11-19.
6. Van Wesenbeeck L., Cleiren E., Gram J., Beals R.K., Benichou O., Scopelliti D., et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 2003, 72:763-771.
7. Balemans W., Devogelaer J.P., Cleiren E., Piters E., Caussin E., Van Hul W. Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling. J Bone Miner Res 2007, 22:708-716.
8. Pangrazio A., Boudin E., Piters E., Damante G., Lo Iacono N., D'Elia A.V., et al. Identification of the first deletion in the LRP5 gene in a patient with autosomal dominant osteopetrosis type I. Bone 2011, 49:568-571.
9. Leupin O., Piters E., Halleux C., Hu S., Kramer I., Morvan F., et al. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem 2011, 286:19489-19500.
10. Jones S.E., Jomary C. Secreted Frizzled-related proteins: searching for relationships and patterns. Bioessays 2002, 24:811-820.
11. Kawano Y., Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003, 116:2627-2634.
12. Nakanishi R., Shimizu M., Mori M., Akiyama H., Okudaira S., Otsuki B., et al. Secreted frizzled-related protein 4 is a negative regulator of peak BMD in SAMP6 mice. J Bone Miner Res 2006, 21:1713-1721.
13. Nakanishi R., Akiyama H., Kimura H., Otsuki B., Shimizu M., Tsuboyama T., et al. Osteoblast-targeted expression of Sfrp4 in mice results in low bone mass. J Bone Miner Res 2008, 23:271-277.
14. Bodine P.V., Zhao W., Kharode Y.P., Bex F.J., Lambert A.J., Goad M.B., et al. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol 2004, 18:1222-1237.
15. Bodine P.V., Billiard J., Moran R.A., Ponce-de-Leon H., McLarney S., Mangine A., et al. The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. J Cell Biochem 2005, 96:1212-1230.
16. Boudin E., Piters E., Nielsen T.L., Andersen M., Roef G., Taes Y., et al. Single nucleotide polymorphisms in sFRP4 are associated with bone and body composition related parameters in Danish but not in Belgian men. Mol Genet Metab 2012, 106:366-374.
17. Boudin E., Piters E., Fransen E., Nielsen T.L., Andersen M., Roef G., et al. Association study of common variants in the sFRP1 gene region and parameters of bone strength and body composition in two independent healthy Caucasian male cohorts. Mol Genet Metab 2012, 105:508-515.
18. Collette N.M., Genetos D.C., Economides A.N., Xie L., Shahnazari M., Yao W., et al. Targeted deletion of Sost distal enhancer increases bone formation and bone mass. Proc Natl Acad Sci U S A 2012, 109:14092-14097.
19. Leupin O., Kramer I., Collette N.M., Loots G.G., Natt F., Kneissel M., et al. Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res 2007, 22:1957-1967.
20. Rozen S., Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000, 132:365-386.
21. Piters E., Culha C., Moester M., Van Bezooijen R., Adriaensen D., Mueller T., et al. First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function. Hum Mutat 2010, 31:E1526-E1543.
22. Dogan R.I., Getoor L., Wilbur W.J., Mount S.M. SplicePort-an interactive splice-site analysis tool. Nucleic Acids Res 2007, 35:W285-W291.
23. Hebsgaard S.M., Korning P.G., Tolstrup N., Engelbrecht J., Rouze P., Brunak S. Splice site prediction in Arabidopsis thaliana pre-mRNA by combining local and global sequence information. Nucleic Acids Res 1996, 24:3439-3452.
24. Adzhubei I.A., Schmidt S., Peshkin L., Ramensky V.E., Gerasimova A., Bork P., et al. A method and server for predicting damaging missense mutations. Nat Methods 2010, 7:248-249.
25. Ng P.C., Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003, 31:3812-3814.
26. Ng P.C., Henikoff S. Predicting deleterious amino acid substitutions. Genome Res 2001, 11:863-874.
27. Ramensky V., Bork P., Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res 2002, 30:3894-3900.
28. Kim S.J., Bieganski T., Sohn Y.B., Kozlowski K., Semenov M., Okamoto N., et al. Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia. Hum Genet 2011, 129:497-502.
29. Bovolenta P., Esteve P., Ruiz J.M., Cisneros E., Lopez-Rios J. Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. J Cell Sci 2008, 121:737-746.
30. Ohnaka K., Yamamoto K., Nakamura K., Adachi M., Kawate H., Kono S., et al. Association of single nucleotide polymorphisms in secreted frizzled-related protein 1 gene with bone mineral density in Japanese women. Geriatr Gerontol Int 2009, 9:304-309.
31. Sims A.M., Shephard N., Carter K., Doan T., Dowling A., Duncan E.L., et al. Genetic analyses in a sample of individuals with high or low BMD shows association with multiple Wnt pathway genes. J Bone Miner Res 2008, 23:499-506.
32. Styrkarsdottir U., Halldorsson B.V., Gretarsdottir S., Gudbjartsson D.F., Walters G.B., Ingvarsson T., et al. Multiple genetic loci for bone mineral density and fractures. N Engl J Med 2008, 358:2355-2365.
33. Boudin E., Piters E., Fransen E., Nielsen T.L., Andersen M., Roef G., et al. Association study of common variants in the sFRP1 gene region and parameters of bone strength and body composition in two independent healthy Caucasian male cohorts. Mol Genet Metab. 2012, 105:508-515.
34. Brommage R. Elevated trabecular bone mass with reduced cortical bone thickness in sFRP4 knockout mice 2009.